Chemist + Druggist is part of Pharma Intelligence UK Limited

This is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.


This copy is for your personal, non-commercial use. Please do not redistribute without permission.

Printed By

UsernamePublicRestriction

Codeine linctus: Pharmacist struck off over opioid street drug ingredient supply

Muhammad Qasim Ali Manzoor supplied a pharmacist “friend” with the ingredients for recreational drug “Lean” over the course of three years, the GPhC’s fitness to practise (FtP) committee found.

A pharmacist has been struck off the register for the supply of codeine linctus and Phenergan (promethazine) “for the purpose of misuse”, a General Pharmaceutical Council (GPhC) FtP committee determined at a hearing held between May 22 and 24.

Muhammad Qasim Ali Manzoor, registration number 2203578, sold the drugs to his “friend” between 2017 and 2020, knowing that they would be “abused in the form of a drug known as Lean”, according to the determination.

On the basis of text message evidence, the FtP committee found that Manzoor had “offered to supply and supplied” a fellow pharmacist, unnamed in the papers, with phenergan and codeine linctus - which was referred to as “Lean” in the correspondence.

Read more: Codeine linctus to be reclassified to POM status over 'risk of abuse'

A witness clarified to the committee that promethazine and codeine linctus are combined to produce the recreational drug “Lean” - also known as “Purple Drank” and used for a “legal high” – according to the document.

The committee accepted that Manzoor, who was not present or represented at the hearing, had a previously unblemished record as a pharmacist and had not “repeated his actions”.

The regulator also accepted that there was “no direct evidence” of supply.

Read more: ‘Overwhelmed’ locum suspended for four months over codeine payment mix-up

Nevertheless, the committee inferred from the context of the messages provided as evidence and on “the balance of probabilities” that “supplies had taken place”.

And it said that Manzoor had “effectively admitted his involvement” in his statement to the regulator. 

 

Suspicious messages

 

In April 2021, Manzoor’s “very serious” misconduct came to light during an investigation into “another pharmacist” who the investigator suspected of “stealing and selling drugs from his pharmacy”, the document revealed.

When inspected, the other pharmacist’s phone revealed “a large number of messages” between this pharmacist and “somebody recorded as Qasim”, it said.

These messages “appeared to discuss” the supply of the opioid codeine linctus and promethazine by “Qasim” to the other pharmacist, it added.

Read more: Pharmacist struck off for illegitimate codeine supply after threats to family

A witness confirmed that the phone number recorded for “Qasim” was the same number that the GPhC had in its records for Manzoor, the document said.

Manzoor and the other pharmacist were well known to each other, having graduated “from the same university in the same year and month”, it added.

The messages revealed that the other pharmacist repeatedly asked Manzoor for promethazine - referred to as “prometh” and “pheng” - and a coded order for “bottles” of another substance ordered “alongside” the antihistamine and Lean ingredient, it said.

Read more: ‘Clear message’: GPhC issues warnings for prescribing via online questionnaires

In 2020, the other pharmacist dropped the pretence and asked Manzoor for “a set” of Lean, who gave his friend a time to collect the drugs, according to the document.

The committee determined that the other drug referred to throughout the correspondence was “more likely than not” codeine linctus, since this is the “other ingredient of Lean”.

 

“Sincere apologies”

 

Manzoor provided the GPhC’s investigating committee with a statement in September 2023, in which he provided his “sincere apologies”, the document revealed. 

He said that “a close friend, another pharmacist” had asked to buy “over the counter (OTC) medications” from him. 

Read more: Pharmacist issued warning after fly tipping of ‘personal patient details’

Manzoor conceded in the letter that he had sold the items “without proper consideration” and in doing so had “failed to uphold the standards” of the GPhC.

“This was a clear breach of trust and I acknowledge the gravity of my mistake,” he wrote.

 

“Inadequate” and “discouraging”

 

But the committee found that Manzoor’s statement was “consistent with him having knowingly supplied drugs for misuse” and was “not only inadequate but discouraging”.

It said that he “knew” that the drugs he was supplying to his pharmacist friend would be “very likely to be abused”.

And it found that the “informal nature of the messages” between Manzoor and his friend were “incompatible with supply for professional purposes”.

Read more: ‘Litany of dishonesty’: Pharmacist suspended for wholesaling fraud

The FtP committee determined that Manzoor had committed “serious” misconduct as he breached its standards by putting people “at risk of addiction and other harm”.

While he had “apparently developed some understanding that what he had done was wrong”, this did not demonstrate to the regulator “any understanding of why his misconduct was wrong”, it said.

Read more: Pharmacist struck off over ‘extreme’ child pornography and bestiality images

Manzoor did not provide the committee with “understanding” of his motives or evidence that there would be “no repetition”, it added.

It decided that a “severe sanction” was necessary and chose to remove Manzoor from the register and impose an interim suspension to cover the appeal period. 

Read the determination in full here.

Related Content

Topics

         
Pharmacy Manager
Guernsey
£70,000

Apply Now
Latest News & Analysis
See All
UsernamePublicRestriction

Register

CD138244

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel